Subhashis Banerjee

Company: Bristol Myers Squibb

Job title: Vice-President, Disease Area Head, Rheumatology and Dermatology

Seminars:

First-in-Class: Evaluating the Efficacy & Safety of an Oral Selective Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor in Dermatologic & Other Conditions 11:30 am

Exploring the mechanism of action of deucravacitinib and its impact on biomarkers and clinical outcomes in psoriasis and psoriatic arthritis Delineating the distinct safety profile of deucravacitinib Dermatology and beyond: exploring TYK2 inhibition in other chronic inflammatory disordersRead more

day: Day Two Translational Track AM

Panel Discussion: Defining Remittive Therapy in Dermatology: Perspectives from Industry Experts 8:30 am

Although an attractive goal, how realistic is being symptom free whilst being treatment free? What does remission actually look like in a dermatology context? Is remittive therapy economically viable? How do you price a drug that cures disease? Does remission include an absence of psychological symptoms?Read more

day: Conference Day Two